BioNTech SE (BNTX)
NASDAQ:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$94.00
▲(9.71% Upside)
Action:ReiteratedDate:03/12/26
The score is anchored by strong financial flexibility (low leverage and substantial resources) and constructive earnings-call updates (raised guidance and oncology progress), offset by weak current profitability and uneven cash generation. Technically, the stock is in a bearish trend below key moving averages, which further pressures the overall score, while valuation is inconclusive due to losses and no dividend yield data.
Positive Factors
Balance-sheet strength
A very low leverage profile and a large equity base provide durable financial flexibility to fund R&D, support late-stage trials, and absorb one-time hits. Over the next 2–6 months this reduces solvency risk, enables opportunistic M&A (e.g., CureVac) and limits refinancing pressure.
Negative Factors
Profitability deterioration
The company swung from pandemic-era profits to a sizeable full-year loss driven by lower vaccine demand and higher operating costs. Persistent negative earnings strain retained earnings and complicate reinvestment choices; sustained losses could force reprioritization of programs or spending cuts.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
A very low leverage profile and a large equity base provide durable financial flexibility to fund R&D, support late-stage trials, and absorb one-time hits. Over the next 2–6 months this reduces solvency risk, enables opportunistic M&A (e.g., CureVac) and limits refinancing pressure.
Read all positive factors
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.53B
Dividend YieldN/A
Average Volume (3M)1.37M
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth7.04%
EPS Growth-25.24%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.44
Shares Outstanding252,531,940
10 Day Avg. Volume1,167,208
30 Day Avg. Volume1,373,096
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda-17.52
Forecast
1Y Price Target
$137.47Price Target Upside60.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.28
Revenue Forecast (FY)$2.27B
BioNTech SE Business Overview & Revenue Model
Company Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance mela...
How the Company Makes Money
BioNTech makes money primarily by commercializing products and by partnering with larger pharmaceutical companies to develop, manufacture, and distribute its therapeutics and vaccines. A major revenue driver has been its collaboration with Pfizer ...
BioNTech SE Earnings Call Summary
Earnings Call Date:Nov 03, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Neutral
BioNTech showed strong progress in its oncology programs and financial position, highlighted by increased revenue and strategic advancements. However, challenges include significant financial losses and delays in product submissions due to regulatory discussions.Positive Updates
Increased Revenue and Financial Guidance
Total revenues for Q3 2025 were EUR 1.519 billion, an increase from EUR 1.245 billion in Q3 2024. The company also raised its revenue guidance for 2025 to $2.6 billion to $2.8 billion, primarily due to recognition of USD 700 million from the BMS collaboration.
Negative Updates
Net Loss in Q3 2025
BioNTech reported a net loss of EUR 29 million for Q3 2025 compared to a net income of EUR 198 million in the prior year period, mainly due to settlement disputes.
Read all updates
Q3-2025 Updates
Positive
Negative
Increased Revenue and Financial Guidance
Total revenues for Q3 2025 were EUR 1.519 billion, an increase from EUR 1.245 billion in Q3 2024. The company also raised its revenue guidance for 2025 to $2.6 billion to $2.8 billion, primarily due to recognition of USD 700 million from the BMS collaboration.
Read all positive updates
Company Guidance
During BioNTech's third-quarter 2025 earnings call, the company provided updated financial guidance and detailed progress in its oncology pipeline, particularly focusing on its two priority programs: Pumitamig and mRNA cancer immunotherapies. BioNTech increased its 2025 revenue guidance to $2.6 billion-$2.8 billion, largely due to the recognition of $700 million from its collaboration with Bristol-Myers Squibb (BMS), part of a total $3.5 billion expected by 2028. R&D expenses were revised downwards to €2 billion-€2.2 billion, reflecting efficient portfolio management and prioritization of key programs. The company is advancing Pumitamig through various registrational and signal-seeking trials across multiple cancer types, with first potential launches targeted before the end of the decade. Additionally, BioNTech highlighted the progress of its mRNA immunotherapy platform, including updates from Phase II trials in melanoma, and emphasized its commitment to leveraging AI tools to enhance personalized therapy development.BioNTech SE Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
88
Very Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.76B | 2.75B | 3.82B | 17.31B | 18.98B |
| Gross Profit | 2.14B | 2.21B | 3.22B | 14.32B | 16.07B |
| EBITDA | -256.17M | -367.10M | 1.38B | 13.10B | 15.00B |
| Net Income | -1.09B | -665.30M | 930.30M | 9.43B | 10.29B |
Balance Sheet | |||||
| Total Assets | 21.98B | 22.53B | 23.01B | 23.28B | 15.83B |
| Cash, Cash Equivalents and Short-Term Investments | 14.83B | 16.78B | 16.55B | 14.06B | 2.07B |
| Total Debt | 267.29M | 254.20M | 219.10M | 212.20M | 301.50M |
| Total Liabilities | 2.76B | 3.12B | 2.76B | 3.22B | 3.94B |
| Stockholders Equity | 19.22B | 19.41B | 20.25B | 20.06B | 11.89B |
Cash Flow | |||||
| Free Cash Flow | 269.81M | -244.60M | 4.67B | 13.21B | 735.70M |
| Operating Cash Flow | 438.00M | 207.70M | 5.37B | 13.58B | 889.70M |
| Investing Cash Flow | -2.37B | -2.08B | -6.95B | -35.30M | -566.10M |
| Financing Cash Flow | -50.81M | -45.90M | -778.60M | -1.42B | 94.20M |
BioNTech SE Technical Analysis
Negative
85.68
Price Trends
103.71
Negative
101.32
Negative
103.78
Negative
Market Momentum
-4.85
Positive
34.48
Neutral
15.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 85.68 is below the 20-day moving average (MA) of 93.24, below the 50-day MA of 103.71, and below the 200-day MA of 103.78, indicating a bearish trend. The MACD of -4.85 indicates Positive momentum. The RSI at 34.48 is Neutral, neither overbought nor oversold. The STOCH value of 15.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $22.91B | 16.17 | 19.30% | ― | 13.50% | 17.16% | |
74 Outperform | $17.97B | 14.98 | 29.15% | ― | 18.09% | 3563.21% | |
69 Neutral | $18.98B | ― | -18.32% | ― | -83.82% | -109.22% | |
66 Neutral | $15.96B | 19.82 | 14.32% | ― | 24.98% | 127.06% | |
58 Neutral | $19.57B | -4.07 | -30.15% | ― | -56.00% | -38.95% | |
57 Neutral | $21.53B | -17.95 | -6.03% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BNTX
BioNTech SE
85.68
-5.38
-5.91%
INCY
Incyte
90.30
29.75
49.13%
UTHR
United Therapeutics
522.83
214.56
69.60%
GMAB
Genmab
25.82
6.24
31.87%
MRNA
Moderna
49.56
21.21
74.81%
ROIV
Roivant Sciences
26.52
16.43
162.83%
BioNTech SE Corporate Events
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
Mar 10, 2026
BioNTech reported on March 10, 2026, that its 2025 revenues rose slightly to €2.87 billion, but it swung to a full-year IFRS net loss of €1.14 billion, or €4.70 per diluted share, mainly due to declining COVID-19 vaccine demand a...
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
Mar 10, 2026
On March 10, 2026, BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company dedicated to next-generation mRNA innovations, with a management transition targeted by the end of 202...
BioNTech Adds Chief People Officer to Management Board to Support Oncology Growth Strategy
Jan 28, 2026
On January 28, 2026, BioNTech SE announced that its Supervisory Board has appointed seasoned HR executive Kylie Jimenez to the newly created role of Chief People Officer on the Management Board, effective March 1, 2026. Based at the company’...
BioNTech Outlines 2026 Strategy and Milestones at J.P. Morgan Healthcare Conference
Jan 14, 2026
On January 13, 2026, BioNTech SE delivered a strategic business update at the 44th J.P. Morgan Healthcare Conference in San Francisco, outlining its key focus areas and expected milestones for 2026. Management highlighted ongoing execution of a st...
BioNTech Maps Out Catalyst-Rich 2026 Oncology Agenda at J.P. Morgan Healthcare Conference
Jan 12, 2026
On January 12, 2026, BioNTech SE announced that it will present a strategic business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlining a catalyst-rich 2026 centered on rapid advancement of its oncology pipe...
BioNTech Completes CureVac Takeover and Updates Articles of Association
Jan 6, 2026
On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously announced post-offer reorganization related to BioNTech’s exchange offer for all outstanding CureVac shares, resulting in BioNTech becoming the sole owner ...
BioNTech Completes CureVac Acquisition to Bolster mRNA Leadership
Dec 18, 2025
On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., completing an exchange offer in which approximately 86.75% of CureVac’s outstanding shares were tendered, with a compulsory acquisition of the remaini...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.